Data completeness
2/8 — Basic
ABACAVIR SULFATE (abacavir sulfate) by Cipla is 12.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Abacavir sulfate is a nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral agent used to treat HIV-1 infection. It works by inhibiting HIV reverse transcriptase, preventing viral replication and integration into host cells. The drug is rapidly absorbed orally with 83% bioavailability and distributes extensively into tissues including CSF.
Pre-Launch
This pre-launch generic entry in a mature HIV market signals cost-focused commercialization with likely smaller teams focused on pricing, payer access, and distribution partnerships.
Mechanism of Action
12.1 Mechanism of Action Abacavir is an antiretroviral agent [see ]. 12.3 Pharmacokinetics Pharmacokinetics in Adults The pharmacokinetic properties of abacavir were independent of dose over the range of 300 to 1,200 mg per day. Absorption Following oral administration, abacavir is rapidly absorbed…
Worked on ABACAVIR SULFATE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.